A. Roy
MD and CEO
Notable Quotes
We have been able to maintain our EBITDA sequentially at 11.7% because of our tight controls on the other cost elements.
We are the first one in the country to manufacture cells with this kind of scale.
We have not taken any price correction in Q3 particularly because we wanted to pass on the entire benefit of the GST reduction to the end customer.
If I can fix the balance 8% to that level, we should at least come to double digit level.
We are not too much concerned on whether it is a March or April as long as we are on the track for that.